SCOPUS 정보 검색 플랫폼

Blood

Volumn 123, Issue 8, 2014, Pages 1119-1121

Boldly targeting kinases without mutations

(1) Davids, Matthew S a

a DANA FARBER CANCER INSTITUTE (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRUTON TYROSINE KINASE; IBRUTINIB; IMATINIB;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DRUG TARGETING; GENE MUTATION; HUMAN; NOTE; PRIORITY JOURNAL;

ANIMALS; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKEMIA, MYELOID, ACUTE; MALE; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES;

EID: 84897877064 PISSN: 00064971 EISSN: 15280020 Source Type: Journal
DOI: 10.1182/blood-2013-12-543322 Document Type: Note

Times cited : (6)

References (13)

1
- 84897901864
- Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)
- Woyach JA, Bojnik E, Ruppert AS, et al. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood. 2014;123(8):1207-1213.
- (2014) Blood , vol.123 , Issue.8 , pp. 1207-1213
- Woyach, J.A.¹ Bojnik, E.² Ruppert, A.S.³

2
- 84897853580
- Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia
- Rushworth SA, Murray MY, Zaitseva L, Bowles KM, MacEwan DJ. Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia. Blood. 2014;123(8):1229-1238.
- (2014) Blood , vol.123 , Issue.8 , pp. 1229-1238
- Rushworth, S.A.¹ Murray, M.Y.² Zaitseva, L.³ Bowles, K.M.⁴ MacEwan, D.J.⁵

3
- 33845444046
- Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
- DOI 10.1056/NEJMoa062867
- Druker BJ, Guilhot F, O'Brien SG, et al IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417. (Pubitemid 44903745)
- (2006) New England Journal of Medicine , vol.355 , Issue.23 , pp. 2408-2417
- Druker, B.J.¹ Guilhot, F.² O'Brien, S.G.³ Gathmann, I.⁴ Kantarjian, H.⁵ Gattermann, N.⁶ Deininger, M.W.N.⁷ Silver, R.T.⁸ Goldman, J.M.⁹ Stone, R.M.¹⁰ Cervantes, F.¹¹ Hochhaus, A.¹² Powell, B.L.¹³ Gabrilove, J.L.¹⁴ Rousselot, P.¹⁵ Reiffers, J.¹⁶ Cornelissen, J.J.¹⁷ Hughes, T.¹⁸ Agis, H.¹⁹ Fischer, T.²⁰ more..

4
- 79959795786
- Improved survival with vemurafenib in melanoma with BRAF V600E mutation
- BRIM-3 Study Group
- Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
- (2011) N Engl J Med , vol.364 , Issue.26 , pp. 2507-2516
- Chapman, P.B.¹ Hauschild, A.² Robert, C.³

5
- 78049425319
- Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
- Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693-1703.
- (2010) N Engl J Med , vol.363 , Issue.18 , pp. 1693-1703
- Kwak, E.L.¹ Bang, Y.J.² Camidge, D.R.³

6
- 84868370689
- Targeting the B cell receptor pathway in chronic lymphocytic leukemia
- Davids MS, Brown JR. Targeting the B cell receptor pathway in chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53(12):2362-2370.
- (2012) Leuk Lymphoma , vol.53 , Issue.12 , pp. 2362-2370
- Davids, M.S.¹ Brown, J.R.²

7
- 84865736998
- Targeting the B-cell lymphoma/leukemia 2 family in cancer
- Davids MS, Letai A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol. 2012;30(25):3127-3135.
- (2012) J Clin Oncol , vol.30 , Issue.25 , pp. 3127-3135
- Davids, M.S.¹ Letai, A.²

8
- 84879384673
- Novel cellular therapies for leukemia: CAR-modi fied T cells targeted to the CD19 antigen
- Brentjens RJ, Curran KJ. Novel cellular therapies for leukemia: CAR-modi fied T cells targeted to the CD19 antigen. Hematology Am Soc Hematol Educ Program. 2012;2012:143-151.
- (2012) Hematology Am Soc Hematol Educ Program , vol.2012 , pp. 143-151
- Brentjens, R.J.¹ Curran, K.J.²

9
- 84993703102
- FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: Clinical implications and limitations
- published online ahead of print June 5
- Kayser S, Levis MJ. FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations [published online ahead of print June 5, 2013]. Leuk Lymphoma.
- (2013) Leuk Lymphoma
- Kayser, S.¹ Levis, M.J.²

10
- 84865176364
- The B-cell receptor signaling pathway as a therapeutic target in CLL
- Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;120(6):1175-1184.
- (2012) Blood , vol.120 , Issue.6 , pp. 1175-1184
- Woyach, J.A.¹ Johnson, A.J.² Byrd, J.C.³

11
- 84881225049
- Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
- Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-516.
- (2013) N Engl J Med , vol.369 , Issue.6 , pp. 507-516
- Wang, M.L.¹ Rule, S.² Martin, P.³

12
- 84879748062
- Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
- Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
- (2013) N Engl J Med , vol.369 , Issue.1 , pp. 32-42
- Byrd, J.C.¹ Furman, R.R.² Coutre, S.E.³

13
- 84891373612
- Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL)
- [abstract] Abstract 7014
- Chang BY, Furman RR, ZapatkaM, et al. Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL) [abstract]. J Clin Oncol. 2013;31. Abstract 7014.
- (2013) J Clin Oncol , vol.31
- Chang, B.Y.¹ Furman, R.R.² Zapatka, M.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.